Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- maladaptive pattern of opioid use
- high Addiction Severity Index (ASI) score
- blunting of pleasurable opioid effects
- miosis
- dilated pupils
- shallow/slow respirations or apnea
- needle marks, scars, or necrosis on skin near veins
- unconsciousness
- pulse <40 bpm
Otros factores de diagnóstico
- chronic constipation
- weight loss
- nausea/vomiting
- sedation
- restless sleep/insomnia
- memory impairment
- sneezing
- yawning
- abdominal cramps
- diarrhea
- backache/muscle spasms
- hot and cold flashes
- hypotension
- sedation
- confusion
- slurred speech
- aggressive behavior
- excess perspiration or lacrimation
- rhinorrhea
- restlessness
- piloerection
- tachypnea
- hypertension
- arrhythmias
- seizures
Factores de riesgo
- young age at substance use initiation
- history of a mental health disorder
- history of substance use
- long-term opioid therapy
- childhood trauma
- homelessness/housing instability
- family history of substance use
- criminal justice system involvement
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- Addiction Severity Index (ASI)
- clinical opiate withdrawal scale (COWS)
- urine or saliva drug screen
- gas chromatography-mass spectroscopy (GC-MS)
- serum electrolytes
- CBC
- BUN/creatinine
- LFTs
- hepatitis serology
- HIV serology
- purified protein derivative (PPD) skin test
Pruebas diagnósticas que deben considerarse
- rapid plasma reagin
- blood cultures
- beta human chorionic gonadotropin (beta-hCG)
Algoritmo de tratamiento
nonpregnant adults in inpatient/outpatient medically supervised withdrawal program
nonpregnant adolescents in inpatient/outpatient medically supervised withdrawal program
pregnant women in inpatient/outpatient medically supervised withdrawal program
nonpregnant adults after medically supervised withdrawal or suitable for initial or early maintenance therapy
nonpregnant adolescents after medically supervised withdrawal or suitable for initial or early maintenance therapy
pregnant women after medically supervised withdrawal or suitable for initial or early maintenance therapy
Colaboradores
Autores
Ashwin A. Patkar, MD, MRCPsych
Associate Professor
Medical Director
Duke Addictions Program
Department of Psychiatry and Behavioral Sciences
Duke University Medical Center
Durham
NC
Divulgaciones
AAP is a stockholder in Generys Biopharmaceuticals that has compounds in development for drug addiction (for stimulant use disorder). AAP provides expert testimony for United States Federal Agencies and is an expert reviewer for North Carolina Medical Board.
Jonathan C. Lee, MD
Medical Director
The Farley Center at Williamsburg Place
Williamsburg
Community Assistant Professor
Department of Family Medicine
Eastern Virginia Medical School
Norfolk
Assistant Clinical Professor
Department of Psychiatry
Virginia Commonwealth University
Richmond
VA
Affiliate Assistant Professor
Department of Psychiatric Medicine
East Carolina University
Greenville
NC
Divulgaciones
JCL declares that he has no competing interests.
Agradecimientos
Dr Ashwin A. Patkar and Dr Jonathan C. Lee would like to gratefully acknowledge Dr Douglas M. Burgess, Dr Kamal Bhatia and Dr Srilakshmi Musham, previous contributors to this topic.
They would also like to thank Isabel Patton, who assisted with the 2025 scheduled update.
Divulgaciones
DMB declares that he has no competing interests. KB declares that he has received grant support from National Institutes of Health, Lundbeck, Pfizer, and Titan Pharmaceuticals. SM declares that she has received grant support from Pfizer, Titan Pharmaceuticals, Shire, and the Forest Research Institute. IP declares being an employee of AAP who has declared interests above. IP has coauthored a manuscript with AAP.
Revisores por pares
Christos Kouimtsidis, MBBS, MSc, MRCPsych, PhD
Consultant Psychiatrist and Honorary Senior Lecturer
Institute of Psychiatry
King's College London
London
UK
Divulgaciones
CK declares that he has no competing interests.
George E. Woody, MD
Emeritus Professor
Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania
Philadelphia
PA
Divulgaciones
GEW declares that he has no competing interests. GEW is an author of a number of references cited in this topic.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed, text revision (DSM-5-TR). Washington, DC: American Psychiatric Association; 2022.Texto completo
World Health Organization. WHO releases 2025 update to the International Classification of Diseases (ICD-11). Feb 2025 [Internet publication].Texto completo
American Society of Addiction Medicine. The ASAM national practice guideline for the treatment of opioid use disorder: 2020 focused update. 2020 Mar/Apr;14(2S suppl 1):1-91.Texto completo Resumen
Substance Abuse and Mental Health Services Administration. TIP 63: medications for opioid use disorder. Jul 2021 [internet publication].Texto completo
National Institute for Health and Care Excellence. Drug misuse in over 16s: opioid detoxification. Jul 2007 (reaffirmed 2019) [internet publication].Texto completo
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.

Diferenciales
- Alcohol intoxication
- Sedative intoxication
- Anticholinergic intoxication
Más DiferencialesGuías de práctica clínica
- Clinical practice guideline: assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco)
- Management of opioid use disorder: 2024 update to the national clinical practice guideline
Más Guías de práctica clínicaFolletos para el paciente
Opioid-use disorder
Más Folletos para el pacienteCalculadoras
Clinical Opioid Withdrawal Scale (COWS) for adults and adolescents
Más CalculadorasInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad